| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2013 | US8377679 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 02/19/2013 | US8377663 Cosmetic composition comprising hydroxymethionine and 3-aminopropanesulfonic acid |
| 02/19/2013 | US8377645 Unc-33 like phosphoprotein (ULIP) polypeptide for generating antibodies for use in diagnosis, preventnion and treatment of neurodegenerative and neoplastic disorders |
| 02/19/2013 | US8377639 Compounds for modulating RNA binding proteins and uses therefor |
| 02/19/2013 | US8377487 Mixture of citric flavonoids to improve ruminal fermentation |
| 02/19/2013 | US8377482 Trace elements |
| 02/19/2013 | US8377477 Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof |
| 02/19/2013 | US8377473 Slow release magnesium composition and uses thereof |
| 02/19/2013 | US8377462 PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices |
| 02/19/2013 | US8377461 Multifunctional medical articles |
| 02/19/2013 | US8377428 Low salt forms of polyallylamine |
| 02/19/2013 | US8377424 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents; treatment of gingivitis |
| 02/19/2013 | US8377332 Transition metal complexes and use thereof in organic light emitting diodes—III |
| 02/19/2013 | US8376140 Portable powder delivery system and method |
| 02/19/2013 | US8375947 Introducing aerosol into a ventilator |
| 02/19/2013 | DE202013000748U1 Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit Sprayable liquid formulation for nasal application in particular with increased local residence |
| 02/19/2013 | DE202012104114U1 Tablette mit obesitaskontrollierenden Inhaltsstoffen Tablet with obesitaskontrollierenden ingredients |
| 02/19/2013 | CA2749656A1 Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| 02/19/2013 | CA2738573C Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| 02/19/2013 | CA2716856C Aurora kinase modulators and method of use |
| 02/19/2013 | CA2703257C Benzomorpholine derivatives and methods of use |
| 02/19/2013 | CA2694881C The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression |
| 02/19/2013 | CA2683637C Methods for treating neoplasia with combination of chemotherapeutic agents and radiation |
| 02/19/2013 | CA2658877C Heme oxygenase inhibitors for the treatment of a microbial infection |
| 02/19/2013 | CA2658525C Smac peptidomimetics useful as iap inhibitors |
| 02/19/2013 | CA2634846C Novel arylamidine derivative, salt thereof and antifungal agent containing those |
| 02/19/2013 | CA2616513C Benzylpiperazine derivates useful for the treatment of gastrointestinal disorders |
| 02/19/2013 | CA2612587C Process for preparing amorphous rosuvastatin calcium free of impurities |
| 02/19/2013 | CA2596031C Injectable preparations of diclofenic and its pharmaceutically acceptable salts |
| 02/19/2013 | CA2588148C 1-phenyl-3-piperazine-pyrazoles and pesticidal compositions of matter thereof |
| 02/19/2013 | CA2581493C Taste-masking pharmaceutical compositions |
| 02/19/2013 | CA2578595C Tobacco alkaloid releasing chewing gum |
| 02/19/2013 | CA2577345C Jelly composition |
| 02/19/2013 | CA2573371C Pyrimidines as plk inhibitors |
| 02/19/2013 | CA2572350C Tetrahydroquinolines |
| 02/19/2013 | CA2569716C Hydantoin derivatives for the treatment of obstructive airway diseases |
| 02/19/2013 | CA2566433C Therapeutic agent for bh4-responsive hyperphenylalaninemia |
| 02/19/2013 | CA2560981C Polymer-based sustained release device |
| 02/19/2013 | CA2560256C Heteroaryl piperidine glycine transporter inhibitors |
| 02/19/2013 | CA2559607C Immune response modifier formulations and methods |
| 02/19/2013 | CA2558314C Use of pde iii inhibitors for the reduction of heart size in mammals suffering from heart failure |
| 02/19/2013 | CA2557054C (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor |
| 02/19/2013 | CA2551525C Pharmaceutical composition for thrombin peptide derivatives |
| 02/19/2013 | CA2547820C (s)-2-n-propylamino-5-hydroxytetralin as a d3 agonist |
| 02/19/2013 | CA2538478C A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases |
| 02/19/2013 | CA2532798C Azepine derivatives as pharmaceutical agents |
| 02/19/2013 | CA2508657C Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/19/2013 | CA2486187C Kinase inhibitors |
| 02/19/2013 | CA2485120C Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| 02/19/2013 | CA2480557C Cycloalkylcarboxyl derivatives that stimulate glucose utilization and methods of use |
| 02/19/2013 | CA2469092C Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als) |
| 02/19/2013 | CA2467930C Treatment of pml targeting jc virus agno |
| 02/19/2013 | CA2456551C Tumour inhibiting lanthanum compounds |
| 02/19/2013 | CA2409044C Improved recrystallization processes for obtaining anhydrous optically active lansoprazole |
| 02/19/2013 | CA2276450C A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 02/19/2013 | CA2233570C Detection, prevention and treatment of papillomatous digital dermatitis |
| 02/15/2013 | CA2748794A1 Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
| 02/14/2013 | WO2013023217A1 Method of measuring and monitoring in vivo nitrite levels |
| 02/14/2013 | WO2013023184A1 Kinase inhibitor polymorphs |
| 02/14/2013 | WO2013023155A1 Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| 02/14/2013 | WO2013023145A1 Certain chemical entities, compositions, and methods |
| 02/14/2013 | WO2013023119A1 JAK P13K/mTOR COMBINATION THERAPY |
| 02/14/2013 | WO2013023104A1 Chlorobis copper (i) complex compositions and methods of manufacture and use |
| 02/14/2013 | WO2013023102A1 Inhibiting transient receptor potential ion channel trpa1 |
| 02/14/2013 | WO2013023000A2 Small molecule compounds that control mammal-pathogenic nematodes |
| 02/14/2013 | WO2013022996A2 The utility of nematode small molecules |
| 02/14/2013 | WO2013022984A1 Selective antisense compounds and uses thereof |
| 02/14/2013 | WO2013022969A1 Docetaxel formulations with lipoic acid |
| 02/14/2013 | WO2013022967A1 Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof |
| 02/14/2013 | WO2013022966A1 Linkage modified gapped oligomeric compounds and uses thereof |
| 02/14/2013 | WO2013022960A1 Cabazitaxel pormulations and methods of preparing thereof |
| 02/14/2013 | WO2013022951A1 Composition for treating diabetes and metabolic diseases and a preparation method thereof |
| 02/14/2013 | WO2013022924A1 Pharmaceutical formulations |
| 02/14/2013 | WO2013022919A1 P62-zz chemical inhibitor |
| 02/14/2013 | WO2013022882A1 Combination therapy for treatment of inflammatory demyelinating disease |
| 02/14/2013 | WO2013022827A1 Method of treating acute myelogenous leukemia |
| 02/14/2013 | WO2013022818A1 Novel macrocycles as factor xia inhibitors |
| 02/14/2013 | WO2013022814A1 Cyclic p1 linkers as factor xia inhibitors |
| 02/14/2013 | WO2013022810A1 Chemical compounds |
| 02/14/2013 | WO2013022793A1 Small molecule activators of calcium-activated chloride channels and methods of use |
| 02/14/2013 | WO2013022783A2 Progesterone containing oral dosage forms and related methods |
| 02/14/2013 | WO2013022763A1 Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains |
| 02/14/2013 | WO2013022740A2 Gpr35 ligands and the uses thereof |
| 02/14/2013 | WO2013022550A2 Small molecule inhibitors of ebola and lassa fever viruses |
| 02/14/2013 | WO2013022519A1 Pyrido-pyrimidine derivatives |
| 02/14/2013 | WO2013022369A1 Complex zinc and alpha-chlorocarboxylic acid compounds for treating skin lesions |
| 02/14/2013 | WO2013022312A2 Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a cyp4a inhibitor as an active ingredient |
| 02/14/2013 | WO2013022280A2 N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 02/14/2013 | WO2013022279A2 N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 02/14/2013 | WO2013022278A2 N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 02/14/2013 | WO2013022257A2 Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
| 02/14/2013 | WO2013022243A2 Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient |
| 02/14/2013 | WO2013022238A2 Tricyclic glycosylated derivative compound, a production method therefor, and an immunosuppressant pharmaceutical composition comprising a tacrolimus glycosylation derivative |
| 02/14/2013 | WO2013022201A1 Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| 02/14/2013 | WO2013022139A1 Method for treatment of diseases caused by accumulation of beta-amyloids in brain parenchyma with low concentration thiazolidinedione derivatives |
| 02/14/2013 | WO2013022092A1 Heptamer-type small guide nucleic acid capable of inducing apoptosis of human hematologic cancer cells |
| 02/14/2013 | WO2013022079A1 Method for treating schizophrenia |
| 02/14/2013 | WO2013022059A1 Pharmaceutical composition containing diamine derivative |
| 02/14/2013 | WO2013022047A1 Cyclopropaneamine compound |
| 02/14/2013 | WO2013021935A1 Compound for treating cartilage disorders |